NCNatacha Comandante-Lou

Natacha Comandante-Lou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Natacha Comandante-Lou has a total of 104 co-authors. Here are the top co-authors by number of shared publications:

  • Philip Lawrence De Jager

    Center for Translational & Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York, USA

    8 shared publications
  • Vilas Menon

    Columbia University Irving Medical Center

    5 shared publications
  • Masashi Fujita

    Center for Translational and Computational Neuroimmunology, Columbia University Irving Medical Center, Department of Neurology and the Taub Institute for the Study of Alzheimer’s Disease and the Aging Brain, New York, NY, 10032, United States of America

    3 shared publications
  • Ya Zhang

    Center for Translational and Computational Neuroimmunology, Columbia University Irving Medical Center, Department of Neurology and the Taub Institute for the Study of Alzheimer’s Disease and the Aging Brain, New York, NY, United States of America

    3 shared publications
  • Alex R. Bautista

    Center for Translational & Computational Neuroimmunology, Neuroimmunology Division, Department of Neurology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, United States

    2 shared publications
  • Andrew A. Sproul

    Taub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University Irving Medical Center (CUIMC) New York New York USA

    2 shared publications

Latest Publications

  • Open Access

    Altered microglial communication in brains with Alzheimer's Disease pathology

    by Loren dos Santos, Ricardo A. Vialle, Natacha Comandante-Lou, Gilad Sahar Green, Yanling Wang, Shinya Tasaki, Naomi Habib, Vilas Menon, Phillip De Jager, Roberto Tadeu Raittz, et al.

    Microglia are the resident immune cells of the central nervous system and are highly versatile, continuously monitoring the brain microenvironment with their motile processes and responding to perturbations in diverse ways. Recent studies have revealed substantial functional heterogeneity among microglial states, suggesting that analyzing individual subpopulations is essential to capture specialized signaling programs and disease-associated interactions that would otherwise be obscured in bulk analyses. To better understand how these cells interact, we performed a ligand-receptor communication analysis using single-nucleus RNA sequencing data from the dorsolateral prefrontal cortex, comprising 16 microglial subpopulations together with other myeloid cells identified in brain tissue, including macrophages and monocytes. We characterized the signaling roles of these cell populations, compared individuals with and without neuropathologically defined Alzheimer's disease, and associated cell-pair interactions with AD-related clinical and neuropathological traits. We found that AD was characterized by altered microglial composition and rewiring of intercellular communication, including disease-specific signaling pathways and distinct interaction hubs. Lipid-associated microglia were associated with tau pathology, whereas nuclear receptor signaling microglia were linked to hippocampal sclerosis. These findings were replicated in three independent datasets. Overall, this work provides an initial but comprehensive map of microglial communication in the aging human brain and identifies candidate signaling interactions for future functional validation.

  • Open Access

    Neuroticism is linked to cognitive decline and increased risk of Alzheimer’s disease through dysregulation of excitatory neurons

    by Sneha Sharma, Natacha Comandante-Lou, Yiyi Ma, Masashi Fujita, David A. Bennett, Andrea R. Zammit, Philip L. De Jager

    INTRODUCTION: Neuroticism is an established risk factor for Alzheimer’s disease (AD), yet the molecular mechanisms linking this personality trait to neurodegeneration remain poorly understood. METHODS: We leveraged single-nucleus RNA-sequencing data from longitudinal cohort studies of cognitive aging (n = 655) to investigate the mechanisms mediating the association between neuroticism and AD. RESULTS: We identified two genes associated with neuroticism, both of which are downregulated in excitatory neurons: ADRA1B and LY6E-DT . In addition, we found that neuroticism is associated with enrichment of a specific excitatory neuron subpopulation: Exc.12. Further analysis revealed that Exc.12 partially mediates the relationship between neuroticism and AD, accounting for 12.2% of the total effect. DISCUSSION: The dysregulation of excitatory neurons may represent a key cellular change that links neuroticism to AD.

  • Innate immune signaling and functions in astrocytes

    by Amy X. Guo, Theodore M. Fisher, Natacha Comandante-Lou, Philip L. De Jager, Shane A. Liddelow

    Astrocytes, long considered supportive cells of the central nervous system (CNS), have critical roles in innate immunity. This Review explores immune signaling pathways in astrocytes, including pattern recognition through Toll-like receptors, nucleic acid sensors and inflammasomes. These pathways enable the detection of danger signals and initiate protective responses and endogenous innate immune functions. Downstream signaling pathways, including the interferon, NF-κB and STAT3 pathways, mediate astrocyte reactivity and drive cytokine secretion, antiviral responses, phagocytosis and many other immune functions. While these responses are crucial for CNS health, their dysregulation can contribute to chronic inflammation and neurodegeneration in conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis. Additionally, astrocytes exhibit regional heterogeneity in their immune behaviors, which may influence disease trajectories. We highlight unresolved questions regarding the immune functions of astrocytes, their interplay with professional immune cells and their dual protective and pathological roles.


  • Open Access

    BAG3 coordinates astrocytic proteostasis of Alzheimer’s disease-linked proteins via proteasome, autophagy, and retromer complex interactions

    by Zachary M. Augur, Garrett M. Fogo, Courtney R. Benoit, Gizem Terzioglu, Zachary R. Murphy, Mason R. Arbery, Natacha Comandante-Lou, Duc M. Duong, Nicholas T. Seyfried, Philip L. De Jager, et al.

    Background: Bcl-2-associated athanogene 3 (BAG3) is a mediator of chaperone assisted selective autophagy, and in the brain, most highly expressed in astrocytes. However, its role in astrocytes remains poorly defined. Given the genetic and pathological links of BAG3 to proteostasis and neurodegenerative diseases, we investigated how BAG3 contributes to astrocyte function and Alzheimer’s disease (AD). Methods: SnRNA-seq of the human brain determined cell type expression of BAG3. CRISPR/Cas9 gene editing in human iPSCs, followed by tandem mass tag-mass spectrometry and RNA-sequencing was performed to assess proteomic and transcriptomic changes following BAG3 loss. Co-immunoprecipitation of BAG3 in human astrocytes defined the interactome, with top interactors being validated by western blot (WB), AlphaFold modeling, and proximity ligation assays. In astrocytes, autophagic flux, lysosomal phenotypes, proteasome activity, and endocytic uptake were measured in BAG3 KO and BAG3 WT. Finally, BAG3 expression was assessed in postmortem AD brain by WB and snRNA-seq, and its functional relevance to amyloid-β (Aβ) degradation was tested in co-cultures of BAG3 KO iAs with familial AD neurons. Results: In human brain and iPSC models, BAG3 was most highly expressed in astrocytes. Further, BAG3 loss caused greater proteomic disruption in astrocytes than in neurons. In the absence of BAG3, astrocytes showed reduced autophagy, diminished lysosome abundance and activity, and decreased proteasome function. To uncover molecular binding partners of BAG3 that might influence these phenotypes, we performed co-immunoprecipitation, revealing interactions with HSPB8 and other heat shock proteins, proteasome regulators (PSMD5, PSMF1), and the retromer component, VPS35. Integration of BAG3 KO transcriptomic and proteomic datasets pinpointed AD-relevant proteins under post-translational control of BAG3, which included GFAP, BIN1, and HSPB8. HSPB8 levels were markedly reduced in BAG3-deficient astrocytes with overexpression partially rescuing its levels. Loss of astrocytic BAG3 impaired Aβ clearance in co-culture with APP/PSEN1 mutant neurons, directly linking BAG3 to a disease-relevant astrocyte function. Finally, analysis of postmortem brain tissue revealed BAG3 marks a stress-responsive astrocyte subtype in the brain of aged individuals with AD. Conclusions: BAG3 binds to key regulators of autophagy, proteasome activity, and retromer function to coordinate astrocyte proteostasis, lysosomal function, and Aβ clearance. These findings position BAG3 as a potential therapeutic target and coordinator of glial protein quality control in neurodegeneration.


  • Open Access

    A systems approach uncovers drivers of the multifocal emergence of an astrocyte state contributing to cognitive decline in Alzheimer’s disease

    by Natacha Comandante-Lou, Tsering Lama, Kevin Chen, Jinglong Zhang, Bin Hu, Shuhui Liu, Sarah Heuer, Kristen J. Brennand, Julie Schneider, Lisa Barnes, et al.

    Diverse cellular states have been mapped in Alzheimer’s disease (AD) pathology, but their links to cognitive decline and the tissue signals driving their emergence remain unclear. We assembled a unified single-nucleus atlas from 867 diverse brains. Meta-analysis identified new cell-state associations with AD and prioritized a non-canonical reactive SLC38A2 high SMTN high CACNA1D high astrocyte (Ast10) as a key link between neuropathologies and cognitive decline. To identify regulators of Ast10 emergence, we modeled ligand-receptor relationships. Independent datasets and two spatial modalities validated these drivers and revealed Ast10’s multifocal distribution throughout the neocortex. Mechanistic validation in mouse and human astrocytes confirmed PLXNB1 , JAM2 and SEMA4D as regulators. In cerebrospinal fluid from a SEMA4D-blocking antibody trial, Ast10 markers are pharmacologically modifiable, and their reduction tracks with cognitive stabilization. Ast10 may contribute to cognitive decline through disrupted presynaptic neurotransmitter release and may be a convergence point for AD and other neurodegenerative pathologies, a promising target for enhancing resilience to dementia.


  • Open Access

    HDAC Inhibitors recapitulate Human Disease-Associated Microglia Signatures in vitro

    by Verena Haage, John F. Tuddenham, Alex Bautista, Charles C. White, Frankie Garcia, Ronak Patel, Natacha Comandante-Lou, Victoria Marshe, Rajesh Kumar Soni, Peter A. Sims, et al.

    Disease-associated microglia (DAM), initially described in mouse models of neurodegenerative diseases, have been classified into two related states; starting from a TREM2-independent DAM1 state to a TREM2 dependent state termed DAM2, with each state being characterized by the expression of specific marker genes 1 . Recently, single-cell (sc)RNA-Seq studies have reported the existence of DAMs in humans 2–6 ; however, whether DAMs play beneficial or detrimental roles in the context of neurodegeneration is still under debate 7,8 . Here, we present a pharmacological approach to mimic human DAM in vitro by exposing different human microglia models to selected histone deacetylase (HDAC) inhibitors. We also provide an initial functional characterization of our model system, showing a specific increase of amyloid beta phagocytosis along with a reduction of MCP-1 secretion. Additionally, we report an increase in MITF expression, a transcription factor previously described to drive expression towards the DAM phenotype. We further identify CADM1 , LIPA and SCIN as DAM- marker genes shared across various proposed DAM signatures and in our model systems. Overall, our strategy for targeted microglial polarization bears great potential to further explore human DAM function and biology.


  • Open Access

    Relation of CMV and brain atrophy to trajectories of immunosenescence in diverse populations

    by Hanane Touil, Tain Luquez, Natacha Comandante-Lou, Annie J Lee, Masashi Fujita, Christian Habeck, Alex Kroshilina, Everardo Hegewisch-Solloa, Julie McInvale, Leah Zuroff, et al.

    Summary: Immunosenescence (ISC), the aging of the immune system, has largely been studied in populations of European descent. Here, circulating immune cell cytometric data from African-American, Hispanic, and non-Hispanic White participants were generated. Known and novel age effects were identified using either a meta-analysis approach or a parallel genetic approach. Most results are consistent across the three populations, but some cell populations display evidence of heterogeneity, such as a PD-L1 + CD56 + NK cell subset. The study estimated “Immunological Age” (IA) during physiologic aging. While we found no relation of IA to Multiple Sclerosis, IA is associated with entorhinal cortex atrophy, a presymptomatic feature of Alzheimer’s disease, linking neurodegeneration and peripheral immunity. ISC trajectories were also inferred, highlighting age, CMV status, and genetic ancestry as key influences. Our assessment offers reference ISC trajectories for personalization of assessments of immune function over the life course in diverse populations.


  • Open Access

    Understanding therapeutic tolerance through a mathematical model of drug-induced resistance

    by Eduardo D. Sontag, Jana L. Gevertz, James Greene, Natacha Comandante-Lou, Samantha Prosperi

    There is growing recognition that phenotypic plasticity enables cancer cells to adapt to various environmental conditions. An example of this adaptability is the persistence of an initially sensitive population of cancer cells in the presence of therapeutic agents. Understanding the implications of this drug-induced resistance is essential for predicting transient and long-term tumor tumor dynamics subject to treatment. This paper introduces a mathematical model of this phenomenon of drug-induced resistance which provides excellent fits to time-resolved in vitro experimental data. From observational data of total numbers of cells, the model unravels the relative proportions of sensitive and resistance subpopulations, and quantifies their dynamics as a function of drug dose. The predictions are then validated using data on drug doses which were not used when fitting parameters. The model is then used, in conjunction with optimal control techniques, in order to discover dosing strategies that might lead to better outcomes as quantified by lower total cell volume.


  • Open Access

    A pharmacological toolkit for human microglia identifies Topoisomerase I inhibitors as immunomodulators for Alzheimer’s disease

    by Verena Haage, John F. Tuddenham, Natacha Comandante-Lou, Alex Bautista, Anna Monzel, Rebecca Chiu, Masashi Fujita, Frankie G. Garcia, Prabesh Bhattarai, Ronak Patel, et al.

    : While efforts to identify microglial subtypes have recently accelerated, the relation of transcriptomically defined states to function has been largely limited to in silico annotations. Here, we characterize a set of pharmacological compounds that have been proposed to polarize human microglia towards two distinct states – one enriched for AD and MS genes and another characterized by increased expression of antigen presentation genes. Using different model systems including HMC3 cells, iPSC-derived microglia and cerebral organoids, we characterize the effect of these compounds in mimicking human microglial subtypes in vitro . We show that the Topoisomerase I inhibitor Camptothecin induces a CD74 high /MHC high microglial subtype which is specialized in amyloid beta phagocytosis. Camptothecin suppressed amyloid toxicity and restored microglia back to their homeostatic state in a zebrafish amyloid model. Our work provides avenues to recapitulate human microglial subtypes in vitro , enabling functional characterization and providing a foundation for modulating human microglia in vivo .


  • Open Access

    AP-1 transcription factor network explains diverse patterns of cellular plasticity in melanoma cells

    by Natacha Comandante-Lou, Douglas G. Baumann, Mohammad Fallahi-Sichani

    Summary: Cellular plasticity associated with fluctuations in transcriptional programs allows individual cells in a tumor to adopt heterogeneous differentiation states and switch phenotype during their adaptive responses to therapies. Despite increasing knowledge of such transcriptional programs, the molecular basis of cellular plasticity remains poorly understood. Here, we combine multiplexed transcriptional and protein measurements at population and single-cell levels with multivariate statistical modeling to show that the state of AP-1 transcription factor network plays a unifying role in explaining diverse patterns of plasticity in melanoma. We find that a regulated balance between AP-1 factors cJUN, JUND, FRA2, FRA1 and cFOS determines the intrinsic diversity of differentiation states and adaptive responses to MAPK inhibitors in melanoma cells. Perturbing this balance through genetic depletion of specific AP-1 proteins, or by MAPK inhibitors, shifts cellular heterogeneity in a predictable fashion. Thus, AP-1 may serve as a critical node for manipulating cellular plasticity with potential therapeutic implications.